Podcasts about Reimbursement

Food as Medicine: Why Medical Nutrition Therapy and Medically Tailored Meals Belong in Modern Healthcare: Registered dietitian nutritionist Leyla Muedin argues that food should be treated with the same rigor as medication through medical nutrition therapy (MNT) and “diet prescriptions,” integrating nutrition into treatment plans rather than leaving it as optional advice. She cites evidence that medically tailored meals (MTMs) can improve outcomes and reduce costs, including a Health Affairs simulation estimating $23.7B in first-year net savings nationwide and a Nature Medicine analysis of a Massachusetts Medicaid demonstration (2020–2023) showing MTM recipients had 31% fewer hospitalizations, 20% fewer emergency visits, and $3,433 lower total healthcare costs, offsetting 98% of program costs. She discusses food insecurity, expanding Medicaid coverage via Section 1115 waivers, EHR integration, and how MTMs support adherence for conditions such as diabetes, cardiovascular disease, chronic kidney disease, depression, and IBS (including low FODMAP).

SLPs have been screaming for a long time that reimbursement is too low, costs are rising, and access to speech-language pathology services is being threatened. But can we prove it with national data?In this episode, Jeanette Benigas, PhD/SLP, introduces The Speech Pathology Education, Advocacy and Knowledge (SPEAK) Project and its first major initiative: building a national economic dataset that shows what it actually costs to provide SLP services and turn those numbers into credible national evidence we can use to advocate directly with CMS during the current public comment period.Jeanette is joined by private practice owner Holly Ellis, MS/SLP, and CPA Cody Underwood to discuss how North Carolina built its own cost analysis, why independent financial analysis matters, and what the national SPEAK Project will measure, including CPT 92507, dysphagia and cognitive services, treatment time, payer mix, Medicare and Medicaid reimbursement, workforce pressures, waitlists, and access to care.The immediate goal: collect high-quality data from all 50 states (+ DC) and turn that evidence into meaningful advocacy.Give data. Give dollars. Or do both.Everything starts at speakproject.net.Get caught up, wherever you stream podcasts!#110: CPT 92507 Is Being Deleted? What Every SLP Must Know About the New Speech Therapy Codes#111: CPT 92507 Q&A for SLPs: Your Questions Answered#113: CPT 92507 Option B: This Is Our Week to Advocate#115: CMS's NEW Pediatric G Code Explained: What Every SLP Needs to Know#116: What the New Speech Therapy Codes Mean for Adult SLPs#117: The End of CPT 92507: Is Your SLP Documentation Ready?✨ Grateful to Chomper Champs for bringing so much positivity and fun to the pediatric SLP space. Follow the link to order the

Today - Cochise County Sheriff Mark Dannels says Arizona’s southern border is now “manageable,” as state and local officials seek more than 902 million dollars in federal reimbursement for years of border-security spending.Support the show: https://www.myheraldreview.com/site/forms/subscription_services/See omnystudio.com/listener for privacy information.

Today - Cochise County Sheriff Mark Dannels says Arizona’s southern border is now “manageable,” as state and local officials seek more than 902 million dollars in federal reimbursement for years of border-security spending.Support the show: https://www.myheraldreview.com/site/forms/subscription_services/See omnystudio.com/listener for privacy information.

This episode of PT Breakfast Club starts with Jimmy McKay reporting from Prompt HQ after a trip to Portland for APTA's Payment Summit and House of Delegates.Jimmy explains how he got in trouble for live tweeting the House of Delegates, why he likes the word “payment” more than “reimbursement,” and what it felt like watching the profession debate policy language in real time.Dave Kittle pushes hard on the bigger question: has payment advocacy actually moved the needle for physical therapy? If insurance companies and Medicare are not meaningfully increasing payment, should more PTs stop waiting and build direct-to-consumer cash-pay offers?Tony Maritato adds the counterpoint: maybe some advocacy success is measured by slowing the decline, not producing giant wins.Then the show turns into a business strategy clinic thanks to Grandpa the Mailbox Guy.For $320, he solves the whole mailbox problem. No hourly rate. No overexplaining. No “here are the 17 steps.” Just a clear result at a clear price.The crew applies that lesson to PT, including grab bar installation, home safety consults, cash-pay evaluations, AI content ideas, therapist recruiting, viral video formats, and what practices should do when a clinician calls out sick.The takeaway: keep it stunningly simple. The customer does not want your process. They want the problem solved.

South Africa says it is asking Nigeria, Malawi and Ethiopia to share the cost of deporting tens of thousands of illegal immigrants to their home countries. The country's Department of Home Affairs says it spent nearly $18 million in the exercise, far exceeding the budgetary allocation. About 82,000 people were repatriated to their home countries since anti-migrant protests started. And a UN report says one in three people can't afford a healthy diet, despite a decline in global hunger in recent years. How are families across Africa coping with the affordability crisis?Presenter: Nkechi Ogbonna Producers: Basma El Atti, Keikantse Shumba and Ayuba Iliya Senior Producer: Charles Gitonga Technical Producer: David Kinyanjui Editors: Rhoda Odhiambo and Maryam Abdalla

Catch Up on the latest leading news stories around the country with Mandy Wiener on Midday Report from 12:00 to 13:00. The Midday Report with Mandy Wiener is 702 and CapeTalk’s flagship news show, your hour of essential news radio. The show is podcasted every weekday, allowing you to catch up with a 60-minute weekday wrap of the day's main news. It's packed with fast-paced interviews with the day’s newsmakers, as well as those who can make sense of the news and explain what's happening in your world. All the interviews are podcasted for you to catch up and listen to. Thank you for listening to this podcast of The Midday Report Listen live on weekdays between 12:00 and 13:00 (SA Time) to The Midday Report broadcast on 702 https://buff.ly/gk3y0Kj and on CapeTalk https://buff.ly/NnFM3Nk For more from The Midday Report go to https://buff.ly/BTGmL9H and find all the catch-up podcasts here https://buff.ly/LcbDdFI Subscribe to the 702 and CapeTalk daily and weekly newsletters https://buff.ly/v5mfetc Follow us on social media: 702 on Facebook: https://www.facebook.com/TalkRadio702 702 on TikTok: https://www.tiktok.com/@talkradio702 702 on Instagram: https://www.instagram.com/talkradio702/ 702 on X: https://x.com/Radio702 702 on YouTube: https://www.youtube.com/@radio702 CapeTalk on Facebook: https://www.facebook.com/CapeTalk CapeTalk on TikTok: https://www.tiktok.com/@capetalk CapeTalk on Instagram: https://www.instagram.com/ CapeTalk on X: https://x.com/CapeTalk See omnystudio.com/listener for privacy information.

The Midday Report with Mandy Wiener is 702 and CapeTalk’s flagship news show, your hour of essential news radio. The show is podcasted every weekday, allowing you to catch up with a 60-minute weekday wrap of the day's main news. It's packed with fast-paced interviews with the day’s newsmakers, as well as those who can make sense of the news and explain what's happening in your world. All the interviews are podcasted for you to catch up and listen to. Thank you for listening to this podcast of The Midday Report Listen live on weekdays between 12:00 and 13:00 (SA Time) to The Midday Report broadcast on 702 https://buff.ly/gk3y0Kj and on CapeTalk https://buff.ly/NnFM3Nk For more from The Midday Report go to https://buff.ly/BTGmL9H and find all the catch-up podcasts here https://buff.ly/LcbDdFI Subscribe to the 702 and CapeTalk daily and weekly newsletters https://buff.ly/v5mfetc Follow us on social media: 702 on Facebook: https://www.facebook.com/TalkRadio702 702 on TikTok: https://www.tiktok.com/@talkradio702 702 on Instagram: https://www.instagram.com/talkradio702/ 702 on X: https://x.com/Radio702 702 on YouTube: https://www.youtube.com/@radio702 CapeTalk on Facebook: https://www.facebook.com/CapeTalk CapeTalk on TikTok: https://www.tiktok.com/@capetalk CapeTalk on Instagram: https://www.instagram.com/ CapeTalk on X: https://x.com/CapeTalk CapeTalk on YouTube: https://www.youtube.com/@CapeTalk567See omnystudio.com/listener for privacy information.

Show recorded on 27/7/26 Released 10/8/26 58 minutes In which we read through some correspondence and find out how things are going with the booking service and getting reimbursements for tests cancelled by the DVSA. Correspondence Test Waiting Times Traffic Light Fun Six Service Wait Reporting Booking Service Misuse Cancellation Fee Costs Links Report Abuse of Booking System

Reimbursement keeps shrinking — but your profit doesn't have to. In this episode, Shaun Kirk breaks down why most practice owners don't actually have a marketing problem, they have an operations problem, and shows exactly where the money is quietly leaking out of your clinic.Drawing on his experience as a private practice consultant and separately running 180+ locations as a VP of Operations in private equity, he walks through:The "leaky bucket" — why roughly 50% of your caseload is already past patients, and what that means for your true patient lifetime valueThe five places profit disappears: front desk control, clinician execution, patient experience, billing/coding, and systemsWhy "2 to 3 times a week" isn't a real plan of care until your team can actually hold that line — and how to fix itThe cluster-booking trick that changes how busy (and profitable) your schedule feelsA real example of adding just $7 per visit in average reimbursement — and what it took operationally to get thereIf you've been telling yourself "we just need more new patients," this episode might change your mind — and show you where the real leaks are hiding.Ready to find your own leaks and fix them for good? Shaun's 6-Week Practice Accelerator is a live, guided program where he personally analyzes your practice, finds where revenue is slipping through the cracks, and builds a week-by-week plan to plug it.

In this episode, host Dr. Nick Rainey is joined by Dr. Bremen Abuhl and Dr. Dallas Ehrmantraut to discuss their 2025 Physical Therapy Journal article, “First Contact Physical Therapy Compared to Usual Primary Care for Musculoskeletal Disorders: A Systematic Review and Meta-Analysis of RCTs.”The conversation explores whether physical therapists should serve as the first point of contact for patients with musculoskeletal disorders and how first contact PT compares with usual primary care.Dr. Abuhl and Dr. Ehrmantraut discuss their findings, including reduced imaging utilization, reduced prescription medication utilization, and similar clinical outcomes for pain, disability, and health-related quality of life. They also unpack the terminology around direct access, first contact PT, and primary care PT, and explain why direct triage models may offer a more efficient pathway for patients.The episode also addresses real-world implementation barriers, including reimbursement models, state scope-of-practice variation, imaging privileges, medication prescribing, stakeholder buy-in, and the need for PTs to step confidently into first contact roles.Key TakeawaysFirst contact PT is not the same as direct access. Direct access means patients can choose PT without referral. First contact PT means the PT is the first provider evaluating the patient for that episode of care.The study found lower healthcare utilization. First contact PT was associated with 45% less imaging and 71% less prescription medication utilization compared with usual primary care.Clinical outcomes were similar. Pain, disability, and health-related quality of life outcomes were statistically similar between first contact PT and usual primary care.Less imaging is not automatically the goal. The more important question is appropriate utilization: avoiding both overuse and underuse.Implementation is a system problem. Scope of practice, reimbursement, stakeholder buy-in, state law, and health system workflows all influence whether first contact PT can work.Direct triage may be the stronger model. Compared with warm handoffs, direct triage allows patients with appropriate MSK presentations to start with PT as the first provider.PTs need to be ready for real-world first contact care. That includes identifying red flags, determining urgency, ordering or recommending imaging when appropriate, and referring to the right provider when needed. Chapters: 00:00 — Welcome and guest introductions 01:17 — Dr. Bremen Abuhl's path into first contact PT research 03:13 — Dr. Dallas Ehrmantraut's clinical spark for the topic 06:16 — Overview of the PTJ systematic review and meta-analysis 09:52 — Direct access vs first contact PT vs primary care PT 13:15 — Global evidence and limited U.S.-based RCTs 16:24 — Imaging findings and appropriate utilization 20:37 — Medication utilization findings 23:27 — Clinical outcomes: pain, disability, and quality of life 25:20 — Study limitations and downstream utilization 27:13 — Why longer-term outcomes matter 31:15 — Risk of bias and crossover between groups 33:36 — U.S. system barriers to first contact PT 36:37 — Reimbursement, payer models, and stakeholder concerns 40:45 — Direct triage vs warm handoff models 44:15 — Scope of practice and state-level barriers 46:08 — Real-world safety, red flags, and PT decision-making 48:01 — Call to action for physical therapists 50:06 — Closing thoughts

The Big Grass Fire in Owyhee County isn't the only wildfire burning in Idaho.

In this episode of Medsider Radio, we sat down with David Veino, President and CEO of Neuros Medical.Neuros is commercializing the FDA-approved Altius Direct Electrical Nerve Stimulation System for chronic post-amputation pain.Before Neuros, David held senior commercial leadership roles at Cardiovascular Systems (CSI) and Stryker, and helped grow CSI's coronary and peripheral business from approximately $50 million to more than $250 million in annual revenue while leading key amputation-prevention initiatives. He also serves as a private equity advisor with Sectoral Asset Management. In this interview, David discusses how commercialization begins by mapping the patient journey upstream, what it takes to generate gold-standard clinical evidence for a novel therapy, how investors assess scalable medtech businesses, and how to build an investor pitch that earns the next meeting.  Before we dive into the discussion, I wanted to mention a few things:First, if you're into learning from medical device founders and CEOs and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.And if you're ready to level up your medtech game, you should check out Medsider Courses — 8-week masterclasses covering topics like fundraising, M&A and exit planning, design and development, clinical and regulatory strategy, and commercialization.These courses, featuring hard-earned lessons from elite medtech CEOs, can be purchased individually or come free with our All-Access Pass.If you'd rather read than listen, here's a link to the full interview with David Veino, which includes a link to ScottBot — an AI version of host Scott Nelson trained on every Medsider interview and playbook. Feel free to ask ScottBot any questions you'd like!KEY MOMENTS FROM THE INTERVIEW(03:02) - David's 30-year medtech journey from cardiovascular devices to leading Neuros (04:38) - How Neuros is treating chronic post-amputation pain with on-demand neuromodulation (11:08) - Why Neuros completely changed its strategy halfway through the pivotal trial (15:36) - Why commercialization starts with referral pathways, not end-users (18:09) - How prosthetists became one of Neuros' most important referral sources (26:11) - What it takes to generate gold-standard clinical evidence for a first-of-its-kind therapy (37:41) - Building an investor pitch that earns the next meeting (41:42) - What gets David excited enough to invest in a medtech company

Host: Maria Berrocal How much money are retina surgeons losing on secondary IOL procedures? In this episode of Clinical Minute: Retina, host Maria Berrocal, MD, speaks with Nimesh "Nemo" Patel, MD, whose research uncovered how many cases are unprofitable under current Medicare reimbursement rates, and assess how much cash surgeons burn per case. Dr. Patel discusses the implications for patient access, the advocacy efforts underway through the ASRS Health Economics Committee, and why closing the gap between reimbursement and operative complexity will require direct engagement with policymakers.

In this episode of Medsider Radio, we sat down with Vijit Sabnis, co-founder and CEO of Adaptyx Biosciences.Adaptyx is a Stanford spinout developing wearable technology for continuous molecular monitoring.Over the past 20 years, Vijit has worked at the intersection of deep technology as an inventor, founder, and investor. Before Adaptyx, he was a Partner at Khosla Ventures and co-founded Solar Junction to commercialize high-efficiency solar cell technology. He holds a Ph.D. in Electrical Engineering from Stanford.In this interview, Vijit discusses how to recognize when a scientific idea is worth building a company around, how to build startup-style learning cycles when spinning technology out of academia, and designing products that are easy for clinicians and consumers to adopt. Before we dive into the discussion, I wanted to mention a few things:First, if you're into learning from medical device founders and CEOs and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.And if you're ready to level up your medtech game, you should check out Medsider Courses — 8-week masterclasses covering topics like fundraising, M&A and exit planning, design and development, clinical and regulatory strategy, and commercialization.These courses, featuring hard-earned lessons from elite medtech CEOs, can be purchased individually or come free with our All-Access Pass.If you'd rather read than listen, here's a link to the full interview with Vijit Sabnis, which includes a link to ScottBot — an AI version of host Scott Nelson trained on every Medsider interview and playbook. Feel free to ask ScottBot any questions you'd like!KEY MOMENTS FROM THE INTERVIEW(03:17) - Vijit's path from Stanford, solar energy, and venture capital to building Adaptyx (07:25) - How Adaptyx is trying to do for hormones what continuous glucose monitors did for diabetes (13:50) - The signals Vijit looked for before founding Adaptyx (25:35) - How Adaptyx turned academic research into startup-speed learning cycles (32:15) - Why cortisol became the company's first clinical application (36:26) - How Adaptyx is designing new molecular data to fit existing clinical workflows (42:12) - Why new consumer health platforms opened new paths to commercialization (47:24) - Fundraising in an era of shorter attention spans

Jim and Chris discuss listener emails on Social Security survivor benefit strategies, a Roth 401(k) catch-up rule loophole, HSA reimbursement for Medicare premiums, pension options including a lump sum rollover, and trust titling versus individual beneficiaries. (13:00) — George asks whether his brother can claim his own Social Security benefit at 62 and switch to the higher survivor benefit at full retirement age. (22:45) — A listener asks whether starting a new job in 2026 could exempt him from the new mandatory Roth 401(k) catch-up rule. (28:45) — The guys field a question about using HSA funds to reimburse Medicare Part A premiums paid for a spouse before age 65. (40:00) — Jim and Chris review a listener’s decision to take a pension lump sum and roll it into an IRA over the annuity options. (1:13:00) — Georgette asks which accounts should be retitled into her trust versus left as individual beneficiary designations. The post Social Security, Roth 401k, HSA Reimbursement, Pension Options, Trust Planning: Q&A #2630 appeared first on The Retirement and IRA Show.

In this episode of The Med-Tech Talent Lab, Mitch Robbins sits down with Spencer Bailey, Vice President of Market Access and Reimbursement at SetPoint Medical, to discuss one of the most critical yet often overlooked aspects of MedTech commercialization: market access.Spencer has built his career at the intersection of healthcare finance, reimbursement, and MedTech innovation. After beginning on the provider side of healthcare and later advising organizations as a healthcare consultant, he transitioned into the medical device industry, where he has helped companies develop reimbursement strategies that support successful commercialization. Today, he leads Market Access and Reimbursement at SetPoint Medical and recently helped secure CMS Transitional Pass-Through Payment for the company's breakthrough technology. SetPoint Medical is pioneering a new approach to treating rheumatoid arthritis with an FDA-approved implantable neuromodulation system that stimulates the vagus nerve to activate the body's natural anti-inflammatory pathways. The therapy represents the first approved neuroimmune modulation treatment for adults with rheumatoid arthritis who have not responded adequately to certain advanced drug therapies.During the conversation, Spencer explains why reimbursement should be viewed as a core business competency instead of an afterthought. He shares how companies can improve their chances of commercial success by bringing market access into the conversation early, often before clinical trials begin. Drawing on his experience across provider organizations, consulting, and MedTech, he offers practical insights on reimbursement strategy, hiring exceptional market access talent, building high-performing teams, and translating complex reimbursement challenges into business strategy.Whether you're a MedTech executive, founder, investor, commercial leader, or reimbursement professional, this episode offers actionable insights on bringing innovative therapies to patients while building a commercialization strategy that lasts.In this episode, you'll learn:• Why market access should be part of product development from day one• When MedTech companies should hire their first market access leader• The biggest misconceptions about reimbursement and commercialization• What separates exceptional market access professionals from the rest• How to build reimbursement teams that create strategic value• Lessons from commercializing a first-of-its-kind medical technology• Where AI will, and will not, change the future of market accessSpencer Bailey on LinkedIn:https://www.linkedin.com/in/spencer-bailey-11ab1410/SetPoint Medical on the web:setpointmedical.com

CMS surprised speech-language pathologists with a proposed pediatric G code, creating new questions about reimbursement, billing, and the future of pediatric speech therapy.In this episode, Jeanette Benigas, PhD/SLP, is joined by billing expert Rick Gawenda and pediatric private practice owner Emily Watkins, MCD/SLP, to break down what the proposed G code actually means, who it applies to, and why it matters far beyond Medicare.Topics include:• Who the proposed pediatric G code applies to• Why commercial insurance and Medicaid may choose different billing paths• Timed CPT codes vs. the proposed G code• How reimbursement could change for pediatric practices• Operational challenges for clinics and business owners• Why giving payers multiple billing options may create inconsistencies• The risks surrounding untimed codes and future payer audits• Why understanding RVUs and practice expense matters• What clinicians and practice owners should consider before submitting comments to CMSWhether you're an employee, private practice owner, school-based SLP, or administrator, these proposed coding changes have the potential to affect your reimbursement, documentation, scheduling, and future practice.This episode is designed to help you understand the proposal, not tell you what position to take, so you can make informed decisions on how to comment before the CMS comment period closes.✨ Grateful to Chomper Champs for bringing so much positivity and fun to the pediatric SLP space. Follow the link to order the

Learn when grantor trusts can reimburse income taxes, key IRS rules, state law differences, and planning strategies for estate planners. The American College of Trust and Estate Counsel, ACTEC, is a professional society of peer-elected trust and estate lawyers in the United States and around the globe. This series offers professionals best practice advice, insights, and commentary on subjects that affect the profession and clients. Learn more in this podcast.

In this episode of Medsider Radio, we sat down with Bob Paulson, President and CEO of Sonex Health. Sonex's UltraGuideCTR device is a minimally invasive technology that enables ultrasound-guided carpal tunnel release procedures to be performed outside the surgical suite using local anesthesia, expanding patient access and reducing the cost of care.Before joining Sonex, Bob led multiple venture-backed medical device companies through commercialization, including NxThera, acquired by Boston Scientific, Restore Medical, acquired by Medtronic, and VentureMed Group. Earlier in his career, he held senior leadership roles at Medtronic, Advanced Bionics, and Endocardial Solutions, which was acquired by St. Jude Medical.In this interview, Bob explains how to build a reimbursement strategy before your first clinical study, drive physician adoption when introducing a new care pathway, and raise capital aligned with value inflection points. Before we dive into the discussion, I wanted to mention a few things:First, if you're into learning from medical device founders and CEOs and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.And if you're ready to level up your medtech game, you should check out Medsider Courses — 8-week masterclasses covering topics like fundraising, M&A and exit planning, design and development, clinical and regulatory strategy, and commercialization.These courses, featuring hard-earned lessons from elite medtech CEOs, can be purchased individually or come free with our All-Access Pass.If you'd rather read than listen, here's a link to the full interview with Bob Paulson, which includes a link to ScottBot — an AI version of host Scott Nelson trained on every Medsider interview and playbook. Feel free to ask ScottBot any questions you'd like!KEY MOMENTS FROM THE INTERVIEW(03:19) - Bob's path from Medtronic to multiple medtech exits before joining Sonex (05:38) - Why 80% of eligible carpal tunnel patients avoid surgery — and how Sonex is changing that (11:11) - The reimbursement challenge that reshaped Sonex's clinical evidence strategy (19:07) - Reimbursement is a three-leg process: FDA, CPT, and payer coverage (22:07) - Reverse engineering your company from the exit you're trying to achieve (29:35) - How Sonex helped surgeons move carpal tunnel procedures out of the OR (39:06) - Sonex's "pitcher-catcher" approach to physician and patient adoption (41:59) - Bob's framework for choosing investors who can finance the entire journey, not just the next round

Taylor Swift Today, one week later, with Lyla: the newlyweds have vanished into married life, the wild details are still trickling out, and we finally know how we'll see the dress. A Dior spokesperson confirmed that Taylor Swift herself will share the first official wedding photos on her own Instagram — no date yet, exactly the way she's controlled this story from day one. Plus the first sighting of Taylor since the wedding (a low-key Montana getaway with her new in-laws), the city reimbursement that settled the "who paid" debate, and a few late details that'll make you smile. Here's the week-later check-in.

TODAY ON THE ROBERT SCOTT BELL SHOW: Reimbursement Code Monopoly, Prof. Dr. Dana Flavin, Foundation for Collaborative Medicine and Research, Hydrangea Arborescens, Politicized Science, Dr. Stephanie Haridopolos, HHS Agenda, Health Freedom, Americans Quitting Multivitamins and MORE! https://robertscottbell.com/reimbursement-code-monopoly-prof-dr-dana-flavin-hydrangea-arborescens-politicized-science-dr-stephanie-haridopolos-americans-quitting-multivitamins/ Purpose and Character The use of copyrighted material on the website is for non-commercial, educational purposes, and is intended to provide benefit to the public through information, critique, teaching, scholarship, or research. Nature of Copyrighted Material Weensure that the copyrighted material used is for supplementary and illustrative purposes and that it contributes significantly to the user's understanding of the content in a non-detrimental way to the commercial value of the original content. Amount and Substantiality Our website uses only the necessary amount of copyrighted material to achieve the intended purpose and does not substitute for the original market of the copyrighted works. Effect on Market Value The use of copyrighted material on our website does not in any way diminish or affect the market value of the original work. We believe that our use constitutes a 'fair use' of any such copyrighted material as provided for in section 107 of the U.S. Copyright Law. If you believe that any content on the website violates your copyright, please contact us providing the necessary information, and we will take appropriate action to address your concern.

In this episode of the Vital Health Podcast, host Duane Schulthess speaks with Michael Penn, US Head of Reimbursement and Public Policy at Sanofi, to discuss how pricing policy, the Inflation Reduction Act (IRA), small-molecule incentives, orphan drug provisions, and Most Favored Nation (MFN) proposals could shape oncology innovation, patient access, and U.S. biopharmaceutical competitiveness. Key Topics: IRA and Oncology: Late-stage research shifts, follow-on studies, lead asset selection. Small-Molecule Incentives: Pill penalty concerns, portfolio reassessment, biologic comparisons. Orphan Drug Policy: Orphan Cures Act provisions, rare disease investment, post-market indication development. Patient Access Risks: Fewer treatment options, affordability questions, unmet needs in oncology. U.S. Competitiveness: MFN proposals, global R&D incentives, comparisons with China and Europe. Our new preprint on the IRA’s impact on late-stage R&D is available on our website and examines declines in small-molecule oncology research and orphan oncology studies. Opinions expressed are those of the speakers. Recorded at ASCO 2026 on 5/31/26. The Vital Health Podcast is a production of Vital Transformation LLC © 2026.See omnystudio.com/listener for privacy information.

Joe Rodriguez (co-founder, Guide Anesthesia) sits down with Randy Moore (EVP and National Chief CRNA, NorthStar Anesthesia) and Gary Keeling (VP of Anesthesia Services, Coronis RCM). Three seats, three vantage points on the same business. Let the spicy takes flow. First docket: the Arizona reimbursement fight. Gary calls the QZ cut a pure money grab. Randy steelmans the insurer's lobbyist before dismantling him, and explains why the hospitals least prepared to absorb the hit will be the ones paying it. Joe walks through why reimbursement parity doesn't raise costs when subsidies fill the gap, and tells the story of the insurer that paid patients directly for eight years. Second docket: the Texas non-compete case. Gary argues exits should hurt but not kill. Randy says hospitals deserve the right to fire bad vendors, but a $30 million buyout is anti-competitive. Joe draws the line between covenants that trap clinicians and the non-solicit rule that just says don't be shady. Plus: why the resume from Hawaii is a red flag, and what the law of inertia does to anesthesia groups that confuse stability with health. Takeaways: The QZ cut is not a savings. It's a transfer. Hospitals backstop anesthesia economics, so a 15% commercial reimbursement cut flows through subsidies to hospitals and ultimately taxpayers, while insurers book the difference. Reimbursement parity does not raise costs in anesthesia. Compensation sits above reimbursement and subsidies fill the gap, so cutting one payer's rate changes who pays, not how much is paid. The facilities that use QZ most are the ones least able to absorb the cut. Rural and underserved programs run closest to the margin, which makes this bad policy independent of the scope debate. CRNAs can lose non-compete fights. In the Texas case, the new employer contractually agreed to cover legal costs and damages, and the court sided with the original group anyway. A buyout promise is not a shield. The covenant you signed is enforceable as written, and "I read online it's unenforceable" is not a legal strategy. The line is solicitation, not competition. A non-solicit protects the group that gave you access to its surgeons and referrals without trapping you in place. Competing down the street is fair game. Taking the business with you is shady. Switching costs are a strategy. A $30 million buyout stops being protection and becomes a hostage situation. Hospitals should be able to fire bad vendors at a price that hurts but doesn't kill. Sign contracts like you plan airways. Have a plan A, B, and C for your exit before the honeymoon period ends, because the group that looks great at signing may not look great in year three. Want more Dr. Joe Rodriguez? Tik Tok: @jrodcrna21 Instagram: @jrod.crna & @abouttherestpod YouTube: @AboutTheRest Thanks for my co-hosts: Randy Moore (EVP & National Chief CRNA, NorthStar Anesthesia) Gary Keeling (VP of Anesthesia Services, Coronis RCM) To Learn More about Human Content Visit: ⁠⁠⁠http://www.human-content.com⁠⁠⁠ To Learn More about About The Rest Visit: www.abouttherest.com Got a Question? hello@abouttherest.com Part of the Human Content Podcast Network Learn more about your ad choices. Visit megaphone.fm/adchoices

A new CEO steps into The Rose and immediately confronts the realities behind 60,000annual screenings: rural healthcare deserts, under‑reimbursed mammograms, and anaging but essential mobile fleet. During this conversation, COO Jessica Duckworth sits down with Angie Lane to talk aboutwhat surprised her most in her first six weeks, why 3D mammography on five pinkcoaches is non‑negotiable for twenty‑six Texas counties with no freestanding imaging,and how shrinking insurance and Medicare payments make patient navigation andfinancial stewardship core to The Rose’s future. Support The Rose HERE. Subscribe to Let’s Talk About Your Breasts on Apple Podcasts, Spotify, iHeart, and wherever you get your podcasts. Key Questions Answered 1. What did Angie learn in her first weeks about serving 60,000 women a year acrossforty‑five counties?2. How do The Rose’s five mobile coaches deliver 3D mammograms in counties with noimaging centers at all?3. Why does Angie describe many of The Rose’s service areas as “healthcare deserts”?4. What does it actually cost The Rose to provide a screening compared to what manyinsurers and Medicare reimburse?5. How does Angie connect her new role to her experience as a working mother who mighthave to lose a day’s work just to reach the medical center?6. Why does she see patient navigation as a uniquely important service for women whoreceive a cancer diagnosis?7. How does Angie’s personal experience hearing a difficult diagnosis about her childshape her empathy for patients at The Rose?8. What financial priorities does Angie name for keeping The Rose stable whilemaintaining high standards of care?9. How does Jessica frame the dual challenge of limited healthcare options and limitedhealth insurance in rural Texas? Timestamped Overview00:00 Jessica welcomes listeners, introduces herself as COO of The Rose, and framesthe episode as a chance for the community to meet new CEO Angie Lane.00:25 Angie thanks Jessica and shares her awe at the scale of The Rose’s work,including serving 60,000 women annually and operating the largest mobilemammography fleet in Texas.00:30 She describes the five RV coaches, their 24‑hour air‑conditioning, bumpy ruralroads, and sophisticated equipment required to bring mammograms to areas withoutfreestanding clinics.01:13 Jessica notes that out of The Rose’s forty‑five‑county service area, twenty‑sixcounties have no freestanding mammography units, making the mobile fleet essential.01:19 She adds that the coaches carry 3D mammography, the gold standard, whichmany local facilities still do not offer.01:33 Angie reflects on growing up near the Texas Medical Center, contrasts thataccess with surrounding counties she now sees as healthcare deserts, and imaginesthe burden on working mothers who would have to take a full day to reach the medicalcenter for routine screening.02:21 Jessica points out that rural communities face deserts in both healthcare servicesand health insurance coverage, compounding access gaps.02:50 Angie explains that providing a mammogram can cost The Rose around $300,while some reimbursements come in around $150–$175, and says closing that gapwithout sacrificing quality is a priority.03:36 Jessica highlights The Rose’s patient navigation program and asks Angie howshe views its importance and future.04:11 Angie calls navigation one of The Rose’s most important services, connects it toher own experience hearing a diagnosis about her child, and underscores howoverwhelming cancer can be even for people already working in healthcare.06:00 Angie talks about the emotional load on patients and families and why having askilled, compassionate navigator alongside them can change the experience oftreatment.07:15 Jessica and Angie touch briefly on funder conversations, the need to explain thatsupport goes far beyond “just a mammogram,” and how navigation, follow‑up, andsystem gaps factor into funding requests.09:30 Angie closes by returning to her core goal: protecting access and quality for everywoman The Rose serves while steering the organization safely through shiftingreimbursement and rural need.See omnystudio.com/listener for privacy information.

Julie Yoo sits down with Dr. Suchi Saria, founder and CEO of Bayesian Health, to discuss the current state of clinical AI and what it takes to deploy AI systems in real-world healthcare settings. While much of the recent attention around AI has focused on copilots, chatbots, and administrative workflows, Saria argues that the greatest opportunity lies in helping clinicians make better decisions at the point of care. She explains how Bayesian Health's clinical intelligence platform continuously analyzes multimodal patient data to identify signs of deterioration, sepsis, and other high-risk conditions before they become medical emergencies. The conversation explores FDA approval, reimbursement, clinician trust, AI governance, hospital workflows, and why healthcare requires a higher standard of evidence than most software categories. Along the way, Saria shares lessons from bringing AI into clinical practice, the future of proactive medicine, and why the next era of healthcare may be defined by continuous intelligence rather than reactive care.   Resources: Follow Suchi Saria on X: https://x.com/suchisaria Follow Julie Yoo on X: https://x.com/julieyoo   Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode of Medsider Radio, we sat down with Dr. Sudhir Srivastava, founder, chairman, and CEO of SS Innovations (Nasdaq: SSII). The company's SSi Mantra surgical robotic system supports a variety of surgical robotic procedures, including cardiac surgery. Sudhir brings more than three decades of experience in minimally invasive and robotic cardiac interventions, having served as Director of Robotic Cardiac Surgery at the University of Chicago and founder of the International College of Robotic Surgery. A pioneer in the field, Sudhir has performed more than 1,400 robotic procedures, including over 750 beating-heart totally endoscopic coronary artery bypass (TECAB) surgeries.In this interview, Sudhir discusses what it takes to democratize robotic surgery beyond affordability, how SS Innovations built teleproctoring, telesurgery, and the supporting infrastructure for its robotic platform, and his milestone-based approach to financing a capital-intensive medtech company. Before we dive into the discussion, I wanted to mention a few things:First, if you're into learning from medical device founders and CEOs and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.And if you're ready to level up your medtech game, you should check out Medsider Courses — 8-week masterclasses covering topics like fundraising, M&A and exit planning, design and development, clinical and regulatory strategy, and commercialization.These courses, featuring hard-earned lessons from elite medtech CEOs, can be purchased individually or come free with our All-Access Pass.If you'd rather read than listen, here's a link to the full interview with Sudhir Srivastava, which includes a link to ScottBot — an AI version of host Scott Nelson trained on every Medsider interview and playbook. Feel free to ask ScottBot any questions you'd like!KEY MOMENTS FROM THE INTERVIEW(03:01) - Sudhir's journey from performing the world's first beating-heart robotic bypass to founding SS Innovations (07:14) - The 22-year-old patient who became the catalyst for Sudhir's affordable robotic surgery platform (08:59) - Building Mantra 3 from the ground up in just five months (12:14) - Inside the engineering process that eliminated months of costly iteration (16:20) - The question that shaped SS Innovations: "How do you democratize access?" (27:10) - From one office to performing 24 telesurgeries in 12 hours across India (29:29) - How a mobile training bus became part of Sudhir's answer to make robotic surgery accessible (33:49) - Lessons from commercializing a surgical robotics platform across developing markets (39:43) - Starting with just $5 million: Sudhir's milestone-based approach to fundraising

See omnystudio.com/listener for privacy information.

Healthcare providers are losing valuable time and revenue navigating an outdated insurance system, but what if artificial intelligence could change everything?In this episode of TechTalk Healthcare, Brad Cost and Dr. Jay Greenstein explore how AI could completely transform healthcare reimbursement, insurance claims processing, fraud detection, and provider payments.Together they discuss why insurance companies continue relying on decades-old systems, how AI could approve claims in milliseconds, and why providers deserve faster, fairer reimbursement.They also dive into the role of government regulation, insurance competition, real-time adjudication, and how data transparency can reshape the future of healthcare.Whether you're a chiropractor, healthcare executive, practice owner, revenue cycle professional, or simply interested in AI's impact on healthcare, this episode offers a thought-provoking look at where the industry is headed.You'll learn:How AI can automate insurance claims processingWhy providers wait weeks (or months) to get paidThe future of real-time claim adjudicationHow AI can reduce healthcare fraudWhy healthcare reimbursement needs reformHow data sharing could strengthen provider advocacyThe role of AI in improving patient access to care

Join Angela Graham BSN, RN, CWOCN Ostomy Coloplast Clinical Specialist and Kelly Seegar MPH, Coloplast Senior Manager Payor Relations, as they introduce the TEAM* model. In this first episode of a three-part series, they break down the TEAM MODEL 101 - exploring what it means clinically and financially. Learn how this payment model is redefining accountability for quality care after a major bowel procedure, and how optimizing the ostomy patient pathway can improve outcomes and help meet ostomy surgery targets.   This episode is ideal for healthcare professionals looking to enhance their ostomy patient pathway and ensure their facilities deliver the best possible patient outcomes while meeting evolving care standards. *Transforming Episode Accountability ModelReimbursement Disclaimer: Coloplast Corp. provides this information for convenience and your general reference only. It does not constitute legal advice or a recommendation regarding clinical practice. Reimbursement, coverage and payment policies can vary from one insurer and region to another and is subject to change without notice. The provider has the responsibility to determine medical necessity and to submit appropriate codes and charges for care provided. Coloplast does not guarantee coverage or payment of products and Coloplast makes no guarantee that the use of this information will prevent differences of opinion or disputes with Medicare, insurers, or other payers as to the correct form of billing or the amount that will be paid. This information is provided for your general information only and is not intended to replace any advice you receive from your own internal or external insurance coverage consultants, reimbursement specialists or legal counsel. Additional resources: ·         Supporting Clinicins in Delivering Coordinated, High-quality Ostomy Care Under the TEAM Model, Article by Kelly Seeger, MPH·         Read more about the TEAM model: TEAM (Transforming Episode Accountability Model) | CMS ·         Learn how to enroll your ostomy patients into the Coloplast Care program: www.coloplastcareconnect.us ·         Visit www.coloplast.professional.us for more offerings! 

In this episode of Medsider Radio, we sat down with Aditya Rajagopal, co-founder and CEO of Esperto Medical.Esperto is a Caltech spin-out utilizing compressed sensing technology with ultrasound to continuously and non-invasively measure blood pressure.Before Esperto, Aditya co-founded ChromaCode, a molecular diagnostics company, and was a researcher at Google[x], where he worked on novel medical imaging methods. Aditya also serves as part-time faculty at Caltech and USC, and holds BS, MS, and PhD degrees in Electrical Engineering from Caltech. In this interview, Aditya discusses why great science doesn't necessarily make great companies, what it takes to win as a fast-follower in medtech, and how to sequence a platform technology without spreading resources too thin.Before we dive into the discussion, I wanted to mention a few things:First, if you're into learning from medical device founders and CEOs and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.And if you're ready to level up your medtech game, you should check out Medsider Courses — 8-week masterclasses covering topics like fundraising, M&A and exit planning, design and development, clinical and regulatory strategy, and commercialization.These courses, featuring hard-earned lessons from elite medtech CEOs, can be purchased individually or come free with our All-Access Pass.If you'd rather read than listen, here's a link to the full interview with Aditya Rajagopal, which includes a link to ScottBot — an AI version of host Scott Nelson trained on every Medsider interview and playbook. Feel free to ask ScottBot any questions you'd like!KEY MOMENTS FROM THE INTERVIEW(02:44) - Aditya's journey from Caltech and Google to tackling one of medicine's hardest engineering problems at Esperto (05:17) - How Esperto is trying to solve a 50-year-old problem: continuous blood pressure monitoring without an arterial catheter (07:17) - Why Esperto was okay with being a fast-follower in an established market instead of creating a new one (16:12) - "Great science doesn't necessarily make great companies" and other lessons Aditya learned at ChromaCode (24:02) - Three hurdles every medical device must clear before clinicians will actually adopt it (27:44) - How Aditya determines whether a technical problem actually has a "there there" (37:51) - Esperto's pitch strategy and how it raised from a position of strength (43:18) - What first-time founders often misunderstand about how venture capital actually works

Another conversation with Dr. Brian Gantwerker Find the video of this conversation at https://youtu.be/Bsyg_f7HoCw

In this episode of Medsider Radio, we sat down with Eric Kau, co-founder and CEO of Climatic.Climatic is commercializing L Max, a daily inhaled system that proactively supports lung function.Before Climatic, Eric served as COO of Seed Health and was part of the foundational team at Chewy. Earlier in his career, Eric held growth and operational leadership roles across consumer, wellness, and e-commerce businesses, including Amazon, BoxyCharm, Target, and Best Buy. In this interview, Eric discusses what it takes to build a consumer category that doesn't yet exist, how Climatic approached clinical validation and consumer education simultaneously, and how early user behavior helped identify the company's strongest initial customer cohorts.Before we dive into the discussion, I wanted to mention a few things:First, if you're into learning from medical device founders and CEOs and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.And if you're ready to level up your medtech game, you should check out Medsider Courses — 8-week masterclasses covering topics like fundraising, M&A and exit planning, design and development, clinical and regulatory strategy, and commercialization.These courses, featuring hard-earned lessons from elite medtech CEOs, can be purchased individually or come free with our All-Access Pass.If you'd rather read than listen, here's a link to the full interview with Eric Kau, which includes a link to ScottBot — an AI version of host Scott Nelson trained on every Medsider interview and playbook. Feel free to ask ScottBot any questions you'd like!KEY MOMENTS FROM THE INTERVIEW(02:49) - Eric's path through Amazon, Chewy, Seed, and the consumer health experiences that led to Climatic (05:49) - Why Climatic is treating lung health like hydration, sleep, or nutrition (11:47) - How Climatic rapidly iterated on formulas, delivery systems, and prototypes to launch a product for a new category in under 2 years (14:56) - Climatic's approach to product design, which is built around gym bags, vanities, and existing wellness routines (19:59) - How early users shaped both Climatic's clinical strategy and its go-to-market focus on endurance athletes and biohackers (23:56) - Why Climatic spent more time teaching consumers about lung health than selling the product itself (34:07) - What investors needed to believe before funding a category that didn't yet exist (40:27) - How Climatic built a 15,000-person waitlist through Strava run clubs instead of paid ads

Ask a burned-out pelvic therapist what's draining them and they'll usually say the same thing: it's a lot. The emotional weight of the work, the intimacy of the specialty, the complexity of the cases.But that's not what's actually breaking providers.Pelvic therapists who love their patients are burning out anyway — because the system they work inside was never designed to sustain them. Documentation that bleeds into evenings. Reimbursement rates that haven't kept pace with inflation in a decade. Visit lengths decided by insurance instead of clinical need. And no business training to help them see the exit before they hit the wall.In this episode, Kelly breaks down the real structural drivers of burnout in pelvic health — the ones that have nothing to do with your caseload and everything to do with the model you inherited. She covers the documentation load nobody warned you about in school, the autonomy gap that comes with insurance dependency, and why this is a practice design problem — not a mindset problem, not a resilience problem, and not a you problem.She also covers what the providers who escaped burnout actually did differently. Not the ones who took a vacation and came back to the same broken model. The ones who restructured and stayed.By the end of this episode, you'll know exactly what broke — and where to start fixing it.KEY TAKEAWAYSPelvic therapist burnout is structural, not personal — it's a model problem built into the system before you ever graduatedDocumentation load, reimbursement erosion, and the autonomy gap are the three real drivers — not patient volume or emotional laborThe providers who escaped burnout didn't work less — they rebuilt the model that was consuming them

ANNOUNCEMENT: If you're a caregiver based in New York State or still have family in New York, join me on Thursday June 18th for my webinar, Caregiving: A Public Health Issue. 8pm est; $15 per person.Sign up here: https://www.eventbrite.com/e/1991026454723?aff=oddtdtcreatorOn this episode of The Social Work Rants Podcast, I discussed the changes to reimbursement rates for providers using CPT codes 90834 and 90837 on the Alma platform, effective July 15th. The changes involve adjusting the rates for session durations, with code 90837 (53 minutes and up) being reimbursed at the same rate as code 90834 (37-52 minute sessions). Basiliso also mentioned the impact of inflation on these changes, citing a recent 4.2% inflation rate.Inflation and Mental Health ConcernsI discuss the impact of inflation on various aspects of life, including healthcare costs and gas prices, noting that while President Biden reduced the national inflation rate, many expenses continue to rise. I expressed concerns about technology platforms like Headway that visually scan patients during mental health sessions, citing ethical issues around patient privacy and surveillance. I also mentioned challenges with audits and payment reimbursements for agencies.I highlight the work of Justin Gillespie from Blue Cross Blue Shield of Michigan, who is working on legislation to address reimbursement rates at both state and national levels.Payer Regulation Impact on NonprofitsI discussed recent payer regulation changes affecting Medicaid and HMO services, including increased denial rates and higher audit frequencies leading to potential nonprofit closures. They highlighted budget issues in New York City affecting nonprofit organizations' ability to pay staff and bills. Basiliso noted that the full impact of the HR1 legislation may not be fully realized until after the November general election.Medicaid Recertification Changes UpdateI also warned about upcoming changes to Medicaid recertifications and a new work requirement effective in July, which will require individuals to show proof of working up to 80 hours to maintain their benefits. These changes will significantly impact vulnerable populations and make social workers' jobs more challenging. The discussion was presented as educational content to help professionals understand the evolving landscape affecting their work.

This week, “Marketplace Morning Report” host Kimberly Adams has been in Thomasville, Alabama as part of our series examining the economic challenges facing rural health care. This morning, we'll look at how low wages in Alabama can mean low Medicare reimbursement rates — shaping how much doctors and nurses get paid, and how much money hospitals and clinics can make. But first, we'll cover how solar power use in the U.S. is hitting new milestones amid energy price fluctuations.

This week, “Marketplace Morning Report” host Kimberly Adams has been in Thomasville, Alabama as part of our series examining the economic challenges facing rural health care. This morning, we'll look at how low wages in Alabama can mean low Medicare reimbursement rates — shaping how much doctors and nurses get paid, and how much money hospitals and clinics can make. But first, we'll cover how solar power use in the U.S. is hitting new milestones amid energy price fluctuations.

In this episode of Medsider Radio, we sat down with Kara Egan, founder and CEO of Teal Health.Teal Health is the company behind the first FDA-authorized at-home cervical cancer screening wand.Before founding Teal, Kara worked in healthcare and software investing at .406 Ventures and Emergence Capital, and held product and marketing roles at Zendesk and Stitch Labs.  In this interview, Kara discusses building support and follow-up into at-home screening, how Teal expanded its comparative clinical study to support broader market adoption, and how healthcare incentives, reimbursement, and institutional trust shape new care models.Before we dive into the discussion, I wanted to mention a few things:First, if you're into learning from medical device founders and CEOs and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.And if you're ready to level up your medtech game, you should check out Medsider Courses — 8-week masterclasses covering topics like fundraising, M&A and exit planning, design and development, clinical and regulatory strategy, and commercialization.These courses, featuring hard-earned lessons from elite medtech CEOs, can be purchased individually or come free with our All-Access Pass.If you'd rather read than listen, here's a link to the full interview with Kara Egan, which includes a link to ScottBot — an AI version of host Scott Nelson trained on every Medsider interview and playbook. Feel free to ask ScottBot any questions you'd like!KEY MOMENTS FROM THE INTERVIEW(02:49) - Kara's background in health technology investing and software that shaped Teal's consumer-first approach (05:14) - How Teal turned the traditional Pap smear into the first FDA-authorized at-home screening product (07:30) - Turning at-home testing, telehealth, and clinician follow-up into a single care experience (13:48) - Raising Teal's first $1M with mockups and consumer-grade design (22:17) - Teal's comparative study that matched physician-collected screening with 96% sensitivity (23:40) - How asking women what they actually wanted changed Teal's view of the market opportunity (32:05) - “Take off the healthcare hat” — Kara's framework for fundraising, incentives, and commercialization (41:48) - What investors actually care about beyond the company's mission

Mayor Gary Moore and City Manager Kasey Mitchell joined Wake Up Tri-Counties to talk about the city-wide cleanup on June 6th, upcoming road construction, the sidewalk reimbursement program, and Hog Days. Kewanee residents are encouraged to take part in city-wide Cleanup Day, which will take place on Saturday, June 6th, from 7 AM until noon. Participants should ensure all items are bagged or boxed for quick unloading, helping keep the area clean and efficient. Proof of an address within Kewanee is required. Volunteers are needed to assist with unloading vehicles and placing materials into large dumpsters. Extra hands are necessary to help the process move smoothly for everyone involved. Anyone interested in volunteering should show up Saturday morning. Join the effort to keep the city looking its best and make a difference in your community. If the event is postponed due to rain, the backup date is next Saturday. Restrictions include no electronics, toner, or liquids such as paint. The city is also promoting involvement in upcoming events, including Hog Days, and highlighting summer construction projects and a sidewalk reimbursement program.

In this episode, Mark Domayhn, Partner at JD Lymon Group, joins Duane Mancini to unpack what medtech innovators often miss most: reimbursement isn't a box to check after FDA—it's the commercial foundation that determines whether hospitals and physicians can adopt your technology. Drawing on experience across Medtronic, Zimmer, and St. Jude/Abbott, Mark breaks down the “three-legged stool” of coverage, coding, and payment, why clinical evidence must satisfy payer standards (not just FDA), and how to “follow the money” across fragmented U.S. systems. The conversation then dives into the New Technology Add-On Payment (NTAP) program, why it matters for inpatient launches, how breakthrough designation has increased NTAP success, and the major implications of CMS proposing to repeal the alternative pathway—plus what companies can do before the June 9 comment deadline. Mark Domyahn LinkedInJD Lymon Group WebsiteRAPID Coverage Pathway InformationDuane Mancini LinkedInProject Medtech WebsiteProject Medtech LinkedInThank you to our sponsors: Ward Law and JumpStart Inc.

In this episode of Medsider Radio, we sat down with Karthik Ganesh, CEO of OnMed.OnMed is the healthcare technology company behind OnMed CareStation, a “Clinic-in-a-Box” designed to expand access to primary and urgent care. Before OnMed, Karthik served as CEO of EmpiRx Health, leading the company through rapid growth and a successful private equity transaction in 2021. Throughout his career, he's held leadership roles at QualCare, CareAllies, and Aetna, and advised healthcare organizations through Deloitte and EY.In this interview, Karthik discusses why hybrid care models still require a human touch, how enterprise healthcare buyers evaluate value propositions differently, why brand and culture should shape execution early, and how operating under constraints can sharpen innovation.Before we dive into the discussion, I wanted to mention a few things:First, if you're into learning from medical device founders and CEOs and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.And if you're ready to level up your medtech game, you should check out Medsider Courses — 8-week masterclasses covering topics like fundraising, M&A and exit planning, design and development, clinical and regulatory strategy, and commercialization.These courses, featuring hard-earned lessons from elite medtech CEOs, can be purchased individually or come free with our All-Access Pass.If you'd rather read than listen, here's a link to the full interview with Karthik Ganesh, which includes a link to ScottBot — an AI version of host Scott Nelson trained on every Medsider interview and playbook. Feel free to ask ScottBot any questions you'd like!KEY MOMENTS FROM THE INTERVIEW(03:04) - Karthik's obsession with healthcare access, and the “broken doorway” problem behind OnMed (05:51) - How OnMed combines telemedicine and brick-and-mortar care into a “Clinic in a Box” (09:04) - The OnMed metrics that surprised Karthik most, including a 37% patient return rate, and the reasons behind the company's success (09:22) - What OnMed designed differently after realizing that patients approach healthcare with their guard up (15:27) - The pitfalls of B2C healthcare and how OnMed was built as a B2B company by intention (22:01) - How Karthik reshaped OnMed around clarity, structure, and high performers (30:23) - What “brand” actually means to Karthik (39:37) - How OnMed tailored its value proposition for payers, providers, employers, and universities (45:45) - Karthik's fundraising philosophy: constraints keep companies inventive

It's Thursday, May 28. Here are today's top stories around Central Indiana. Want to go deeper on the stories you hear on WFYI News Now? Visit wfyi.org and follow us on social media to get local news every day. WFYI News Now is hosted by Barb Anguiano and produced by Zach Bundy. Subscribe wherever you get your podcasts.

Most physical therapists know something's broken. Reimbursements are declining. Administrative burden is rising. And despite delivering massive value, the profession is still treated like an afterthought.In this episode of the Private Practice Owners Podcast, Nathan Shields sits down with Scott Gardner—clinic owner and leader of the United Physical Therapy Association—to unpack the real reason behind the industry's struggles.From the “ancillary provider” label to Medicare policy, Scott breaks down why physical therapists are stuck at the bottom of the healthcare hierarchy—and what it will actually take to change that.This isn't theory. This is a behind-the-scenes look at the legislative, financial, and systemic forces shaping your clinic's future.In this episode, you'll learn:Why physical therapists are still classified as “ancillary” providers—and why it mattersThe real reason reimbursements keep decliningHow Medicare policy directly impacts your clinic revenueWhat MPPPR is (and why it's quietly costing you thousands)The truth about “opting out” of MedicareWhy most therapists complain—but don't take actionHow advocacy and legislation shape the future of private practiceWhat needs to happen for PTs to gain autonomy and higher payWhy unity across clinics may be the only way forwardThis episode is not about quick wins. It's about understanding the system—and how to actually change it.

In this episode of Medsider Radio, we sat down with Dr. Connie Lehman, founder and CEO of Clairity.Clairity is the first FDA-authorized AI platform that predicts a woman's five-year risk of developing breast cancer using only a routine screening mammogram.A physician scientist with over 300 peer-reviewed publications, Connie is a Professor of Radiology at Harvard Medical School and Breast Imaging Specialist at Massachusetts General Brigham (on leave). She holds an MD and PhD from Yale and was named to Forbes' 50 Over 50 Innovators and TIME 100 World's Most Influential Leaders in Health.In this interview, Connie discusses her experience translating academic research into a commercially viable startup, the massive undertaking of generating clinical evidence when you're creating a new category, and how Clairity is approaching adoption on two fronts: fitting into physician workflows and building access pathways for patients.Before we dive into the discussion, I wanted to mention a few things:First, if you're into learning from medical device founders and CEOs and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.And if you're ready to level up your medtech game, you should check out Medsider Courses — 8-week masterclasses covering topics like fundraising, M&A and exit planning, design and development, clinical and regulatory strategy, and commercialization.These courses, featuring hard-earned lessons from elite medtech CEOs, can be purchased individually or come free with our All-Access Pass.If you'd rather read than listen, here's a link to the full interview with Connie Lehman, which includes a link to ScottBot — an AI version of host Scott Nelson trained on every Medsider interview and playbook. Feel free to ask ScottBot any questions you'd like!KEY MOMENTS FROM THE INTERVIEW(03:04) - The broken screening paradigm Connie saw in clinic — and the gap that became Clairity (05:09) - How Clairity rolls the clock back from detection to predicting risk in healthy women (07:31) - Why "more data is better" turned out to be wrong and how that shaped Clairity's product scope (21:57) - How physicians can translate grant-generating discipline into building a company (24:56) - What 18 months of pre-sub meetings revealed about navigating a de novo pathway (26:49) - Why Clairity validated its technology in over 250,000 mammograms when FDA required far less (34:43) - How Connie flipped the natural question from "how can doctors offer this?" to "how can women access it?" (43:47) - How relationships, not pitches, drove Clairity's $43M Series B

Send us Fan MailHospice has always been about people, but the future of hospice will increasingly be shaped by data—and that shift is both exciting and unsettling.In Part Two of The Future of Hospice: How HOPE Will Transform Reimbursement & Care, Raianne Melton and Andrea Hale unpack how the HOPE tool could redefine hospice reimbursement, value-based care, and quality measurement across CMS, Medicare Advantage, and health systems. The conversation explores where hospice measurement may be heading—from symptom impact scoring and burdensome discharges to acuity tracking, HUV utilization, and the growing importance of consistent documentation and actionable clinical data.The episode also focuses on what hospice leaders can do now to prepare: improving point-of-care documentation, simplifying EMR workflows, leveraging real-time analytics, and exploring AI-powered ambient listening to reduce clinician burden while preserving compassionate care. Ultimately, this conversation is about helping hospice organizations prove their value with measurable outcomes while staying true to the mission that defines hospice care.This episode offers practical insights for hospice executives, nonprofit healthcare leaders, clinicians, and anyone navigating the evolving landscape of end-of-life care.Guest:Andrea Hale, CEO of Valley Hospice Raianne Melton, Director of Clinical Services of Professional Services for AxxessHost:Chris Comeaux, President / CEO of TELEIOS and author of The Anatomy of LeadershipThe Anatomy of Leadership podcast explores the art and science of leadership through candid, insightful conversations with thought leaders, innovators, and change-makers from a variety of industries. Hosted by Chris Comeaux, each episode dives into the mindsets, habits, and strategies that empower leaders to thrive in complex, fast-changing environments. With topics ranging from organizational culture and emotional intelligence to navigating disruption and inspiring teams, the show blends real-world stories with practical takeaways. The goal is simple yet ambitious: to equip leaders at every level with the tools, perspectives, and inspiration they need to lead with vision, empathy, and impact.https://www.teleioscn.org/anatomy-of-leadership

Send us Fan MailThe future of hospice care is changing—and the HOPE assessment tool may redefine how providers deliver care, document outcomes, and receive reimbursement.Healthcare is entering a new era where quality outcomes, patient data, and accountability are driving the future of care delivery.  In this episode, we're joined by Andrea Hale, CEO of Valley Hospice, and Raianne Melton, Director of Clinical Services of Professional Services for Axxess, whose expertise and frontline perspective help unpack one of the most significant shifts happening in hospice today—the implementation of the HOPE assessment tool. Their insight provides valuable guidance for hospice leaders, clinicians, and organizations preparing for the future of reimbursement and patient-centered care.In Part One of this important conversation, we explore how the Hospice Outcomes & Patient Evaluation (HOPE) tool is poised to transform the hospice landscape.  From evolving CMS expectations to the growing emphasis on quality metrics and patient-centered outcomes, this episode breaks down what hospice leaders, clinicians, and healthcare organizations need to understand now.Join us as we discuss:• What the HOPE tool is and why it matters• How reimbursement models are shifting in hospice care• The operational and compliance challenges providers may face• Why documentation and quality reporting are becoming more critical than ever• How organizations can proactively prepare for the future of end-of-life careWhether you're a hospice professional, nonprofit executive, healthcare leader, or business decision-maker, this episode provides timely insight into the changing future of compassionate care delivery.Our Guest:Andrea Hale, CEO of Valley HospiceRaianne Melton, Director of Clinical Services of Professional Services for AxxessHost:Chris Comeaux, President / CEO of TELEIOS and author of The Anatomy of Leadership

In this episode of Medsider Radio, we sat down with Antony Odell, co-founder and CEO of Echopoint Medical.Echopoint is a London-based UCL spinout developing iKOr, an optical microcatheter for coronary diagnostics.Antony brings over 30 years of medtech experience across Johnson & Johnson, Fresenius, and Stryker, before transitioning into startups as CEO of Tayside Flow Technologies and Tissue Regenix. He holds a BSc in Physiology and Biochemistry.In this interview, Antony discusses translating academic IP into a commercial device, choosing early clinical sites to balance speed and learning, managing non-dilutive funding as a long-term discipline, and outlines the most important responsibilities of an early-stage medtech CEO.Before we dive into the discussion, I wanted to mention a few things:First, if you're into learning from medical device founders and CEOs and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.And if you're ready to level up your medtech game, you should check out Medsider Courses — 8-week masterclasses covering topics like fundraising, M&A and exit planning, design and development, clinical and regulatory strategy, and commercialization.These courses, featuring hard-earned lessons from elite medtech CEOs, can be purchased individually or come free with our All-Access Pass.If you'd rather read than listen, here's a link to the full interview with Antony Odell, which includes a link to ScottBot — an AI version of host Scott Nelson trained on every Medsider interview and playbook. Feel free to ask ScottBot any questions you'd like!KEY MOMENTS FROM THE INTERVIEW(03:06) - How Antony's career centered on translating clinical insights into commercial reality (05:54) - What Echopoint's iKOr does, and why 40% of cath lab patients leave without a diagnosis (12:13) - How Echopoint landed its first U.S. clinical site, and what that means for the company (13:48) - What to assess before spinning out an academic idea, and why clinician input is the first real test (20:14) - Why Echopoint chose Barts over typical sites for its first-in-human study (22:58) - How getting too close to one clinical site can lead to dangerous groupthink (30:54) - Why non-dilutive funding belongs on the board agenda permanently (39:54) - How CEOs should manage boards, control information flow, and avoid becoming a “glorified note-taker”

Is the Merit-based Incentive Payment System (MIPS) fulfilling its intended purpose, or is it just causing headaches? Dr. George Williams and Joe Reyes join host Dr. Andrew Pouw to share their expertise and experience with MIPS, including its evolultion from prior medical cost control policies and how ophthalmologists can use the IRIS Registry to meet reporting requirements.  For all episodes or to claim CME credit for selected episodes, visit www.aao.org/podcasts

In this episode of Medsider Radio, we sat down with Kurt Jacobus, co-founder and CEO of restor3d.restor3d provides patient-specific orthopedic implants using 3D printing and advanced software.Kurt has over two decades of experience in medtech entrepreneurship, including successful exits to Enovis and NuVasive. Prior to his career in medical devices, Kurt was a consultant at McKinsey & Company. He holds a PhD in Mechanical Engineering and is an Adjunct Professor at Georgia Tech. In this interview, Kurt discusses how restor3d used the FDA's 520(b) pathway to generate revenue and regulatory proof simultaneously, why self-regulating beyond FDA requirements makes submissions a competitive barrier, and how to approach investor relationships and board construction with long-term thinking.Before we dive into the discussion, I wanted to mention a few things:First, if you're into learning from medical device founders and CEOs and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.And if you're ready to level up your medtech game, you should check out Medsider Courses — 8-week masterclasses covering topics like fundraising, M&A and exit planning, design and development, clinical and regulatory strategy, and commercialization.These courses, featuring hard-earned lessons from elite medtech CEOs, can be purchased individually or come free with our All-Access Pass.If you'd rather read than listen, here's a link to the full interview with Kurt Jacobus.KEY MOMENTS FROM THE INTERVIEW(03:21) - How Kurt went from wanting to build race cars to 20 years of orthopedic entrepreneurship (06:03) - How restor3d's patient-specific implants challenge the “8 sizes fit 8 billion people” model (15:36) - Why early-stage companies should “ring the cash register” as soon as possible (17:16) - How a 520(b) pathway helped restor3d generate revenue before full FDA clearance (31:48) - How restor3d treats every FDA submission like a PhD thesis and holds itself to standards beyond what regulators ask for (35:24) - What Kurt learned from restor3d's limited market release (40:03) - How Kurt raised is last$100M+ round, and why fundraising is really a networking game (45:13) - What makes a great board, and how the wrong one can quietly derail a company

The Medicaid provider says it will recoup "overpayments" retroactively.